Industry Growth Insights published a new data on “Ornithine-Transcarbamylase Deficiency Market”. The research report is titled “Ornithine-Transcarbamylase Deficiency Market research by Types (DTX-301, SEL-313, SHP-641, PRX-OTC, Others), By Applications (Hospital, Clinic, Others), By Players/Companies Lucane Pharma SA, PhaseRx Inc, Promethera Biosciences SA, Selecta Biosciences Inc, Translate Bio Inc, Ultragenyx Pharmaceutical Inc, Unicyte AG”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ornithine-Transcarbamylase Deficiency Market Research Report
By Type
DTX-301, SEL-313, SHP-641, PRX-OTC, Others
By Application
Hospital, Clinic, Others
By Companies
Lucane Pharma SA, PhaseRx Inc, Promethera Biosciences SA, Selecta Biosciences Inc, Translate Bio Inc, Ultragenyx Pharmaceutical Inc, Unicyte AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Ornithine-Transcarbamylase Deficiency Market Report Segments:
The global Ornithine-Transcarbamylase Deficiency market is segmented on the basis of:
Types
DTX-301, SEL-313, SHP-641, PRX-OTC, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lucane Pharma SA
- PhaseRx Inc
- Promethera Biosciences SA
- Selecta Biosciences Inc
- Translate Bio Inc
- Ultragenyx Pharmaceutical Inc
- Unicyte AG
Highlights of The Ornithine-Transcarbamylase Deficiency Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- DTX-301
- SEL-313
- SHP-641
- PRX-OTC
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ornithine-Transcarbamylase Deficiency Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ornithine-transcarbamylase deficiency is a rare genetic disorder that results in the inability to break down the amino acid ornithine. This can lead to an accumulation of ornithine in the body, which can cause serious health problems. Symptoms of Ornithine-transcarbamylase deficiency include muscle weakness, seizures, and coma. Treatment typically involves administering a daily dose of an enzyme replacement therapy called carbamoyl phosphate synthase (CPTS) inhibitor.
Some of the key players operating in the ornithine-transcarbamylase deficiency market are Lucane Pharma SA, PhaseRx Inc, Promethera Biosciences SA, Selecta Biosciences Inc, Translate Bio Inc, Ultragenyx Pharmaceutical Inc, Unicyte AG.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ornithine-Transcarbamylase Deficiency Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ornithine-Transcarbamylase Deficiency Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ornithine-Transcarbamylase Deficiency Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ornithine-Transcarbamylase Deficiency Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ornithine-Transcarbamylase Deficiency Market Size & Forecast, 2018-2028
4.5.1 Ornithine-Transcarbamylase Deficiency Market Size and Y-o-Y Growth
4.5.2 Ornithine-Transcarbamylase Deficiency Market Absolute $ Opportunity
Chapter 5 Global Ornithine-Transcarbamylase Deficiency Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Ornithine-Transcarbamylase Deficiency Market Size Forecast by Type
5.2.1 DTX-301
5.2.2 SEL-313
5.2.3 SHP-641
5.2.4 PRX-OTC
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Ornithine-Transcarbamylase Deficiency Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Ornithine-Transcarbamylase Deficiency Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ornithine-Transcarbamylase Deficiency Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ornithine-Transcarbamylase Deficiency Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Ornithine-Transcarbamylase Deficiency Analysis and Forecast
9.1 Introduction
9.2 North America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Type
9.6.1 DTX-301
9.6.2 SEL-313
9.6.3 SHP-641
9.6.4 PRX-OTC
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Ornithine-Transcarbamylase Deficiency Analysis and Forecast
10.1 Introduction
10.2 Europe Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Ornithine-Transcarbamylase Deficiency Market Size Forecast by Type
10.6.1 DTX-301
10.6.2 SEL-313
10.6.3 SHP-641
10.6.4 PRX-OTC
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Ornithine-Transcarbamylase Deficiency Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Ornithine-Transcarbamylase Deficiency Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Ornithine-Transcarbamylase Deficiency Market Size Forecast by Type
11.6.1 DTX-301
11.6.2 SEL-313
11.6.3 SHP-641
11.6.4 PRX-OTC
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Ornithine-Transcarbamylase Deficiency Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Ornithine-Transcarbamylase Deficiency Analysis and Forecast
12.1 Introduction
12.2 Latin America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Type
12.6.1 DTX-301
12.6.2 SEL-313
12.6.3 SHP-641
12.6.4 PRX-OTC
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Ornithine-Transcarbamylase Deficiency Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Ornithine-Transcarbamylase Deficiency Market Size Forecast by Type
13.6.1 DTX-301
13.6.2 SEL-313
13.6.3 SHP-641
13.6.4 PRX-OTC
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Ornithine-Transcarbamylase Deficiency Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ornithine-Transcarbamylase Deficiency Market: Competitive Dashboard
14.2 Global Ornithine-Transcarbamylase Deficiency Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Lucane Pharma SA
14.3.2 PhaseRx Inc
14.3.3 Promethera Biosciences SA
14.3.4 Selecta Biosciences Inc
14.3.5 Translate Bio Inc
14.3.6 Ultragenyx Pharmaceutical Inc
14.3.7 Unicyte AG
